Cortical gets chance to shine in front of Korean investors
BPH Energy (ASX:BPH) investee company Cortical will be granted an opportunity to present its brain scanning technology to potential South Korean investors as part of a trade delegation.
It told the market today that Cortical has been invited by the Australian Trade and Investment Commission to present at the Austrade Medtech Innovation Showcase to be held in Korea.
In attendance will be senior executives from some of Korea’s leading pharmaceutical and medical device companies – attending at a time when the Korean Ministry of Science, ICT, and Future Planning has identified brain research as one of the five main fields to receive funding.
The Korean government has also recently launched the “Creative Economy” industry policy, which is aims to revitalise the Korean manufacturing sector through investment in advanced manufacturing capability in the materials, biotechnology, and healthcare sector.
The partnership between the Australian and Korean biotechnology sectors is also expected to grow on the back of the Free Trade Agreement signed between the two nations at the end of 2014.
News of Cortical’s involvement in the trade delegation comes shortly after it was selected as a semi-finalist in the Australian Technologies Competition (ATC).
The awards are an opportunity for small to medium technology companies to showcase their wares to judges from companies such as Deloitte, Bird&Bird, and FB Rice.
The competition has generated $250 million in investment over the past five years, and over 120 companies have benefitted from the competitions ongoing mentoring program.
There is no indication as yet if BPH will be a beneficiary, so don’t base your investment decision on their selection alone and approach any investment decision with caution.
Selection in the semi-finals of the competition is somewhat of a boon for Cortical, as the competition this year is not only focusing on technology but the ability for a company to globally scale their business.
In both cases, Cortical will be showcasing its brain function monitor (BAR) technology, which purportedly improves on the currently used EEG technologies by incorporating the latest advances in understanding of how the brains rhythmic electrical activity is produced.
The BARs underlying algorithm produces EEG indexes which are directly related to the physiological state of the patient’s brain.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.